The use of monoclonal antibodies and related agents in the treatment of respiratory disease. Drugs of today (Barcelona, Spain : 1998) [Drugs Today (Barc)] Journal article | | Title | The use of monoclonal antibodies and related agents in the treatment of respiratory disease. | | Author(s) | Schachter EN, Neuman T | | Institution | Division of Pulmonary Medicine, Mount Sinai School of Medicine, New York, USA. neil.schachter@mssm.edu. | | Source | Drugs Today (Barc) 2009 Jul; 45(7):533-48. | | Abstract | Monoclonal antibodies were first developed in 1975. Since their introduction they have had a progressively increasing impact on different areas of medical diagnostics and therapeutics. Currently, many monoclonal antibodies are under investigation for their potential role in pulmonary medicine. This review discusses a brief history of monoclonal antibodies; the manufacture, use, biosafety and nomenclature of these agents; the inflammatory response in asthma; and the use of omalizumab, an FDA-approved monoclonal antibody for use in asthma, will be described in detail, as well as its associated adverse effects. Additionally, other related biologic agents that may have a role in respiratory diseases are presented. | | Language | eng | | Pub Type(s) | Journal Article
| | PubMed ID | 19834630 |
|
|
| |
Advertise on this site.
| | |
|
